ARMH3

Across TCGA pan-cancer cohorts, ARMH3 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ARMH3 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ARMH3 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ARMH3 expression acts as an unfavorable survival marker, although some lineages such as HNSC and PDAC show a favorable association.

HNSC, PDAC, and UCEC are the cancer types where ARMH3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	1.000	0.449	.023	25	view →
PDAC	OS	Median	II,III,IV	0.631	0.354	<.001	17	view →
UCEC	DFS	Quartile	All	0.959	0.754	.027	12	view →
GBM	DFS	Quartile	All	0.446	0.169	.022	7	view →
LUAD	OS	Quartile	III,IV	0.680	0.207	.022	6	view →
CCRCC	OS	Tertile	III,IV	0.554	0.840	.043	2	view →
LSCC	DFS	Quartile	II,III,IV	1.000	0.907	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ARMH3–HNSC (OS)

Open the HNSC breakdown →